387 related articles for article (PubMed ID: 16996863)
1. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).
Ray KK; Morrow DA; Shui A; Rifai N; Cannon CP
Am J Cardiol; 2006 Oct; 98(7):861-5. PubMed ID: 16996863
[TBL] [Abstract][Full Text] [Related]
2. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
3. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
4. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
[TBL] [Abstract][Full Text] [Related]
5. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes.
Postadzhiyan AS; Tzontcheva AV; Kehayov I; Finkov B
Clin Biochem; 2008 Feb; 41(3):126-33. PubMed ID: 18061588
[TBL] [Abstract][Full Text] [Related]
6. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting.
van der Harst P; Voors AA; Volbeda M; Buikema H; van Veldhuisen DJ; van Gilst WH
Am J Cardiol; 2006 Jun; 97(12):1697-701. PubMed ID: 16765116
[TBL] [Abstract][Full Text] [Related]
8. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
[TBL] [Abstract][Full Text] [Related]
9. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl.
Spencer FA; Goldberg RJ; Gore JM; Fox KA; Avezum A; Agnelli G; Kritharides L; Anderson FA; Goodman SG; FitzGerald G; Allegrone J; Brieger D;
Am J Cardiol; 2007 Sep; 100(6):913-8. PubMed ID: 17826369
[TBL] [Abstract][Full Text] [Related]
10. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
[TBL] [Abstract][Full Text] [Related]
11. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes.
O'Malley T; Ludlam CA; Riemermsa RA; Fox KA
Eur Heart J; 2001 Jul; 22(14):1226-34. PubMed ID: 11440495
[TBL] [Abstract][Full Text] [Related]
12. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Wiviott SD; Cannon CP; Morrow DA; Ray KK; Pfeffer MA; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1411-6. PubMed ID: 16226163
[TBL] [Abstract][Full Text] [Related]
13. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
14. The case for intensive statin therapy after acute coronary syndromes.
Schwartz GG; Olsson AG
Am J Cardiol; 2005 Sep; 96(5A):45F-53F. PubMed ID: 16126023
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
[TBL] [Abstract][Full Text] [Related]
17. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial).
Assali AR; Moustapha A; Sdringola S; Denktas AE; Willerson JT; Holmes DR; Smalling RW
Am J Cardiol; 2006 Sep; 98(6):729-33. PubMed ID: 16950172
[TBL] [Abstract][Full Text] [Related]
18. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Ray KK; Cannon CP
Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024
[TBL] [Abstract][Full Text] [Related]
19. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates.
Baessler A; Fischer M; Huf V; Mell S; Hengstenberg C; Mayer B; Holmer S; Riegger G; Schunkert H
Int J Cardiol; 2005 May; 101(2):293-8. PubMed ID: 15882678
[TBL] [Abstract][Full Text] [Related]
20. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
